RxDoctor Payments DataLook up a doctor →

Michael White

Physician Assistant · Dallas, TXNPI 1265600357

Payments from drug & device makers

$275,611in general payments, 2019–2025

Across 1,052 payments — averaging $261.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$108K
  • Johnson & Johnson$97K
  • Endo Pharmaceuticals Inc.$18K
  • Endo USA, Inc.$14K
  • Accord Healthcare, Inc.$13K
  • Janssen Scientific Affairs, LLC$7K
  • plus $19K from 33 others

What the payments were for

  • Consulting fees$30,17811%
  • Speaking & faculty fees$178,84365%
  • Travel & lodging$31,35011%
  • Food & beverage$34,81513%
  • Education$4250%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$275,611 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$66,501
Medicare patients
155
Services billed
2,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide69$974,821
OrgovyxRelugolix37$93,819
GemtesaVibegron57$52,305
MyrbetriqMirabegron38$26,705
Abiraterone Acetate26$10,680
Silodosin75$5,588
Mirabegron ErMirabegron13$5,331
Testosterone Cypionate83$4,423
Potassium Citrate ErPotassium Citrate31$3,362
Tamsulosin Hcl160$1,647
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst37$831
Alfuzosin Hcl ErAlfuzosin Hcl27$782
Finasteride83$721
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim132$561
Bethanechol Chloride12$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$96,927$974,82169 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$625$146,12494 claims
Astellas Pharma US IncMyrbetriq$460$26,70538 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$7,146$10,68026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →